Altace Co-Promotion Lawsuit Spurs Question About King's Ability To Launch Nebivolol
This article was originally published in The Pink Sheet Daily
Executive Summary
An investment firm says Wyeth's lawsuit alleging King failed to meet its detailing obligations for Altace raises "concern" that King will lack the manpower needed to promote Mylan's beta blocker. Mylan says the King acquisition is the best strategy for maximizing nebivolol.
You may also be interested in...
Relationship With Wyeth "Much Improved" Despite Altace Lawsuit, King Says
King says its relationship with Wyeth is "much improved" despite an ongoing breach of contract lawsuit over the companies' co-promotion deal for Altace
Relationship With Wyeth "Much Improved" Despite Altace Lawsuit, King Says
King says its relationship with Wyeth is "much improved" despite an ongoing breach of contract lawsuit over the companies' co-promotion deal for Altace
Mylan/King Merger, GSK's Fluarix Expected To Highlight Oct. 28 Earnings Calls
Also reporting on Oct. 28 are Elan, ImClone and Medco. Final heavy week of quarterly pharma earnings updates include Oct. 27 reports by P&G, Merck KGaA and Novo Nordisk.